6:20 PM
 | 
Oct 23, 2012
 |  BC Extra  |  Clinical News

Celgene's pomalidomide meets MM endpoint

Celgene Corp. (NASDAQ:CELG) said pomalidomide plus low-dose dexamethasone met the primary endpoint of progression-free survival (PFS) vs. high-dose dexamethasone in the Phase III MM-003 trial to treat relapsed and/or...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >